Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
E2F3
REST API REST API
Homo sapiens
E2F3 is differentially expressed in 296 experiments: 136 organism parts: bone marrow, cerebellum, ... (134 more);, 202 disease states: normal, control, ... (200 more);, 105 cell types 385 cell lines 38 compound treatments and 78 other conditions.
Orthologs F1P324_CHICK (Gallus gallus)   E2F3 (Bos taurus)   E2F3 (Danio rerio)   LOC100361421 (Rattus norvegicus)   E2f3 (Mus musculus)   E2f (Drosophila melanogaster)   e2f3 (Xenopus laevis)   E2F3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cyclin-dependent protein kinase activity, DNA binding, protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, positive regulation of cell proliferation, mitotic cell cycle, G1 phase of mitotic cell cycle, nucleus, transcription factor complex, transcription initiation from RNA polymerase II promoter, nucleoplasm, positive regulation of transcription, DNA-dependent, G2 phase of mitotic cell cycle, sequence-specific DNA binding transcription factor activity
InterPro Term E2F_TDP
UniProt Accession Q499G5, O00716, Q68DT0, Q24JQ3, F5H536
Search EB-eye ENSG00000112242
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (34 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (41 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
SW480
1
3
E-MTAB-37, E-GEOD-18005, E-GEOD-2509, E-MEXP-1014
primary culture
2
E-GEOD-1657, E-GEOD-2450
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
379 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (47 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-GEOD-6740, E-TABM-145
B cell
2
2
E-GEOD-3982, E-GEOD-13987
plasma cell
2
E-MEXP-2360, E-GEOD-6691
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
neutrophil
2
E-GEOD-12662, E-GEOD-3982
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (59 experiments)

Factor Value U/D Experiments
control
4
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121, E-GEOD-16728
glioblastoma
1
3
E-GEOD-6014, E-GEOD-4290, E-MTAB-37, E-MTAB-62
lung adenocarcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514, E-MEXP-231
adenocarcinoma
2
E-MTAB-37, E-MEXP-1331
hepatocellular carcinoma
2
E-MTAB-37, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
196 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5258, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (26 experiments)

Factor Value U/D Experiments
none
4
7
E-GEOD-20719, E-GEOD-5824, E-MEXP-1958, E-GEOD-2803, E-GEOD-5099, ... (11 experiments)
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-3720, E-TABM-868
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
TNF
1
E-GEOD-15205
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
glucose
1
E-MEXP-941
32 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (9 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-20847, E-MTAB-108, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-TABM-321, E-TABM-868, E-GEOD-18005, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-GEOD-20504, E-GEOD-22278, E-MEXP-1741, ... (7 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-302, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-GEOD-1926, E-MEXP-2069, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-9723, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-22541

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-1561, E-GEOD-4922

Processing time: 0.439 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM